Longitudinal Assessment of Curaçao Criteria in Children with Hereditary Hemorrhagic Telangiectasia.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 19 05 2023
revised: 03 08 2023
accepted: 06 08 2023
medline: 27 11 2023
pubmed: 13 8 2023
entrez: 12 8 2023
Statut: ppublish

Résumé

To assess the utility of the Curaçao criteria by age over time in children with hereditary hemorrhagic telangiectasia (HHT). This was a single-center, retrospective analysis of patients attending the HHT clinic at the Hospital for Sick Children (Toronto, Canada) between 2000 and 2019. The evaluation of the Curaçao criteria was completed during initial and follow-up visits. Screening for pulmonary and brain arteriovenous malformations was completed at 5 yearly intervals. A total of 116 patients with genetic confirmation of HHT were included in the analysis. At initial screening at a median (IQR) age of 8.4 (2.8, 12.9) years, 41% met criteria for a definite clinical diagnosis (≥3 criteria). In children <6 years at presentation, only 23% fulfilled at least 3 criteria initially. In longitudinal follow-up, 63% reached a definite clinical diagnosis, with a median (IQR) follow-up duration of 5.2 (3.2, 7.9) years (P = .005). Specifically, more patients met the epistaxis and telangiectasia criteria at last visit compared with initial (79% vs 60%; P = .006; 47% vs 30%; P = .02) but not for the arteriovenous malformation criterion (59% vs 57%; P = .65). In the pediatric population, most patients do not meet definite clinical criteria of HHT at initial presentation. Although the number of diagnostic criteria met increased over time, mainly due to new onset of epistaxis and telangiectasia, accuracy remained low during follow-up visits. Relying solely on clinical criteria may lead to underdiagnosis of HHT in children.

Identifiants

pubmed: 37572862
pii: S0022-3476(23)00528-0
doi: 10.1016/j.jpeds.2023.113665
pii:
doi:

Substances chimiques

Endoglin 0
Activin Receptors, Type II EC 2.7.11.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113665

Informations de copyright

Crown Copyright © 2023. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicts of interest.

Auteurs

Mordechai Pollak (M)

Pediatric Respiratory Division, The Hospital for Sick Children, Toronto, Ontario, Canada; Pediatric Pulmonology Institute, The Ruth Rappaport Children's Hospital, Rambam Health Campus, Haifa, Israel. Electronic address: m_pollak@rambam.health.gov.il.

Dvir Gatt (D)

Pediatric Respiratory Division, The Hospital for Sick Children, Toronto, Ontario, Canada.

Michelle Shaw (M)

Translational Medicine, SickKids Research Institute, Toronto, Ontario, Canada.

Sheryl L Hewko (SL)

Translational Medicine, SickKids Research Institute, Toronto, Ontario, Canada.

Anthony Lamanna (A)

Translational Medicine, SickKids Research Institute, Toronto, Ontario, Canada.

Sara Santos (S)

Translational Medicine, SickKids Research Institute, Toronto, Ontario, Canada.

Felix Ratjen (F)

Pediatric Respiratory Division, The Hospital for Sick Children, Toronto, Ontario, Canada; Translational Medicine, SickKids Research Institute, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH